Publicado

2023-03-23

Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis

Adipocinas séricas como biomarcadores para el seguimiento terapéutico de pacientes con enfermedades inflamatorias intestinales (EII) tratados con infliximab: revisión sistemática y metanálisis

Adipocinas séricas como biomarcadores para monitoramento terapêutico de pacientes com doenças inflamatórias intestinais (DIIs) tratados com infliximabe: revisão sistemática e metanálise

DOI:

https://doi.org/10.15446/rcciquifa.v51n3.107328

Palabras clave:

Therapeutic monitoring, Infliximab, Leptin, Adiponectin, Resistin, Inflammatory Bowel Diseases (en)
Seguimiento terapéutico, infliximab, leptina, adiponectina, resistina, enfermedades inflamatorias intestinales (es)
Acompanhamento terapêutico, infliximabe, leptina, adiponectina, resistina, doenças inflamatórias intestinais (pt)

Descargas

Autores/as

  • William Gustavo Lima Laboratório de Radioisótopos, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
  • Patrícia Alcântara Cândido Laboratório de Radioisótopos, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
  • Adriano de Paula Sabino Laboratório de Hematologia, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
  • Valbert Nascimento Cardoso Laboratório de Radioisótopos, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
  • Simone Odília Antunes Fernandes Laboratório de Radioisótopos, Departamento de Análises Clínicas, Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, MG.
Introduction: Inflammatory bowel diseases (IBDs) are idiopathic inflammations of the colon, which can often undergo remission with the use of specific anti-TNF antibodies such as the infliximab. Although that the therapeutic monitoring can provide valuable insight into the possible etiolog y of unfavorable outcomes and allow for an appropriate management strateg y for these patients, currently none technique or biomarker have proved ideal for the evaluation of therapeutic benefices of anti-TNF antibodies in IBDs. Aim: To summarise current knowledge on the role of serum adipokines as potential biomarkers for the therapeutic monitoring of patients with IBDs under infliximab. Methods: A systematic review was carried out in the PubMed/MEDLINE, Cochrane Library, Scopus and Biblioteca Virtual em Saúde databases. Next, the meta-analysis was performed with the mean values of serum adipokine levels in patients with IBDs before and after the use of infliximab using the Review Manager (RevMan) ® 5.3 software. Results: Three studies that together included 58 patients diagnosed with IBDs and treated with infliximab at 5 mg/kg were selected. According to the quantitative analysis, serum leptin levels were significantly increased after the use of infliximab (p-value=0.01; Heterogeneity: I2=61%), which is correlated with the clinical remission of the disease. In addition, the circulating adiponectin (p-value=0.006; Heterogeneity: I2=0%) and resistin (p-value=0.009; Heterogeneity: I2=93%) concentrations were both reduced after the clinical remission of IBD with the use of infliximab. Conclusion: Serum leptin levels are significantly increased, while circulating adiponectin and resistin is reduced among IBD patients after the use of infliximab.

Introducción: las enfermedades inflamatorias intestinales (EII) son inflamaciones idiopáticas del colon, que en muchas ocasiones pueden entrar en remisión con el uso de anticuerpos anti-TNF específicos, como el infliximab. Aunque el seguimiento terapéutico puede proporcionar información valiosa sobre la posible etiología de los desenlaces desfavorables y permitir una estrategia de manejo adecuada para estos pacientes, actualmente ninguna técnica o biomarcador ha demostrado ser ideal para evaluar los beneficios terapéuticos de los anticuerpos anti-TNF en las EII. Objetivo: resumir el conocimiento actual sobre el papel de las adipocinas séricas como biomarcadores potenciales para el seguimiento terapéutico de pacientes con EII que utilizan infliximab. Métodos: Se realizó una revisión sistemática en las bases de datos PubMed/MEDLINE, Cochrane Library, Scopus y Virtual Health Library. Luego, se realizó un metanálisis con los valores medios de los niveles de adipoquinas séricas en pacientes con EII antes y después del uso de infliximab, utilizando el software Review Manager (RevMan)® 5.3. Resultados: se seleccionaron tres estudios que en conjunto incluyeron 58 pacientes diagnosticados de EII y tratados con infliximab a dosis de 5 mg/kg. Según el análisis cuantitativo, los niveles de leptina sérica aumentaron significativamente después del uso de infliximab (valor de p = 0,01; Heterogeneidad: I2 = 61 %), lo que se correlaciona con la remisión clínica de la enfermedad. Además, las concentraciones circulantes de adiponectina (valor de p = 0,006; heterogeneidad: I2 = 0 %) y resistina (valor de p = 0,009; heterogeneidad: I2 = 93 %) se redujeron después de la remisión clínica de la EII con el uso de infliximab. Conclusión: los niveles de leptina sérica aumentan significativamente, mientras que la adiponectina y la resistina circulantes se reducen entre los pacientes con EII después del uso de infliximab.

Introdução: as doenças inflamatórias intestinais (DIIs) são inflamações idiopáticas do cólon, que muitas vezes podem sofrer remissão com o uso de anticorpos anti-TNF específicos, como o infliximabe. Embora o monitoramento terapêutico possa fornecer informações valiosas sobre a possível etiologia de desfechos desfavoráveis e permitir uma estratégia de manejo adequada para esses pacientes, atualmente nenhuma técnica ou biomarcador se mostrou ideal para a avaliação dos benefícios terapêuticos dos anticorpos anti-TNF em DIIs. Objetivo: resumir o conhecimento atual sobre o papel das adipocinas séricas como potenciais biomarcadores para o monitoramento terapêutico de pacientes com DII em uso de infliximabe. Métodos:foi realizada revisão sistemática nas bases de dados PubMed/MEDLINE, Cochrane Library, Scopus e Biblioteca Virtual em Saúde. Em seguida, foi realizada a meta-análise com os valores médios dos níveis séricos de adipocinas em pacientes com DII antes e após o uso de infliximabe, utilizando o software Review Manager (RevMan) ® 5.3. Resultados: três estudos que juntos incluíram 58 pacientes diagnosticados com DII e tratados com infliximabe na dose de 5 mg/kg foram selecionados. De acordo com a análise quantitativa, os níveis séricos de leptina aumentaram significativamente após o uso de infliximabe (valor de p=0,01; Heterogeneidade: I2=61%), o que está correlacionado com a remissão clínica da doença. Além disso, as concentrações circulantes de adiponectina (valor de p=0,006; heterogeneidade: I2=0%) e resistina (valor de p=0,009; heterogeneidade: I2=93%) foram ambas reduzidas após a remissão clínica da DII com o uso de infliximabe. Conclusão: os níveis séricos de leptina estão significativamente aumentados, enquanto a adiponectina e a resistina circulantes estão reduzidas entre os pacientes com DII após o uso de infliximabe.

Referencias

J.T. Chang, Pathophysiology of Inflammatory Bowel Diseases, New England Journal of Medicine, 383, 2652-2664 (2020).

H.-J. Su, Y.-T. Chiu, C.-T. Chiu, Y.-C. Lin, C.-Y. Wang, J.-Y. Hsieh, S.-C. Wei, Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates, Journal of the Formosan Medical Association, 118, 1083-1092 (2018).

K.B. Gecse, S. Vermeire, Differential diagnosis of inflammatory bowel disease: imitations and complications, The Lancet, Gastroenterology & Hepatology, 3, 644-653 (2018).

S.C. Ng, H.Y. Shi, N. Hamidi, F.E. Underwood, W. Tang, E.I. Benchimol, R. Panaccione, S. Ghosh, J.C.Y. Wu, F.K.L. Chan, J.J.Y. Sung, G.G. Kaplan, Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies, Lancet (London, England), 390, 2769-2778 (2018).

J.M. Dahlhamer, E.P. Zammitti, B.W. Ward, A.G. Wheaton, J.B. Croft, Prevalence of inflammatory bowel disease among adults aged ≥18 years — United States, 2015, Morbidity and Mortality Weekly Report, 65, 1166-1169 (2016).

J. Côté-Daigneault, M. Bouin, R. Lahaie, J.F. Colombel, P. Poitras, Biologics in inflammatory bowel disease: what are the data?, United European Gastroenterology Journal, 3, 419-428 (2015).

P. Rawla, T. Sunkara, J.P. Raj, Role of biologics and biosimilars in inflammatory bowel disease: Current trends and future perspectives, Journal of Inflammatory Research, 11, 215-226 (2018).

R. Ferreiro, M. Barreiro-de Acosta, Infliximab in inflammatory bowel disease, in: A.D. Medrano-Acevedo (editor), Infliximab: Pharmacology, Uses and Limitations, Nova Science Publishers, Inc., 2012, pp. 39-74.

A.N. Sasson, A.N. Ananthakrishnan, M. Raman, Diet in Treatment of Inflammatory Bowel Diseases, Clinical Gastroenterology and Hepatology, 19, 425-435 (2021).

U. Kopylov, S. Ben-Horin, E. Seidman, Therapeutic drug monitoring in inflammatory bowel disease, Annals of Gastroenterology, 27, 304-312 (2014).

E.L. Barnes, R. Burakoff, New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes, Inflammatory Bowel Disease, 22, 2956-2965 (2016).

C. Fink, I. Karagiannides, K. Bakirtzi, C. Pothoulakis, Adipose tissue and inflammatory bowel disease pathogenesis, Inflammatory Bowel Disease, 18, 1550-1557 (2012).

M. Waluga, M. Hartleb, G. Boryczka, M. Kukla, K. Zwirska-Korczala, Serum adipokines in inflammatory bowel disease, World Journal of Gastroenterology, 20, 6912-6917 (2014).

T. Karrasch, A. Schaeffler, Adipokines and the role of visceral adipose tissue in inflammatory bowel disease., Annals of Gastroenterology, 29, 424-438 (2016).

V.S. Rodrigues, M. Milanski, J.J. Fagundes, A.S. Torsoni, M.L.S. Ayrizono, C.E.C. Nunez, C.B. Dias, L.R. Meirelles, S. Dalal, C.S.R. Coy, L.A. Velloso, R.F. Leal, Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn’s disease, Clinical & Experimental Immunology, 170, 358-364 (2012).

N. Ouchi, J.L. Parker, J.J. Lugus, K. Walsh, Adipokines in inflammation and metabolic disease, Nature Revew Immunology, 11, 85-97 (2011).

K. Karmiris, I.E. Koutroubakis, C. Xidakis, M. Polychronaki, T. Voudouri, E.A. Kouroumalis, Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease, Inflammatory Bowel Disease, 12, 100-105 (2006).

F. Trejo-Vazquez, I. Garza-Veloz, G.A. Villela-Ramirez, Y. Ortiz-Castro, P. Mauricio-Saucedo, E. Cardenas-Vargas, M. Diaz-Baez, M.A. Cid-Baez, R. Castañeda-Miranda, J.M. Ortiz-Rodriguez, L.O. Solis-Sanchez, M.L. Martinez- Fierro, Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study, Experimental and Therapeutic Medicine, 15, 3336-3344 (2018).

L.G.F. de Carvalho, W.G. Lima, L.G.V. Coelho, V.N. Cardoso, S.O.A. Fernandes, Circulating leptin levels as a potential biomarker in inflammatory bowel diseases: A systematic review and meta-analysis, Inflammatory Bowel Disease, 27, 169-181 (2021)

R. Kahraman, T. Calhan, A. Sahin, K. Ozdil, Z. Caliskan, E.S. Bireller, B. Cakmakoglu, Are adipocytokines inflammatory or metabolic mediators in patients with inflammatory bowel disease?, Therapeutics and Clinical Risk Management, 13, 1295-1301 (2017).

D. Franchimont, S. Roland, T. Gustot, E. Quertinmont, Y. Toubouti, M.-C. Gervy, J. Deviere, A. Van Gossum, Impact of infliximab on serum leptin levels in patients with Crohn’s disease, The Journal of Clinical Endocrinology & Metabolism, 90, 3510-3516 (2005).

K. Frivolt, T. Schwerd, S.B. Schatz, F. Freudenberg, C. Prell, K.J. Werkstetter, P. Bufler, S. Koletzko, Hyperadiponectinemia During Infliximab Induction Therapy in Pediatric Crohn Disease, Journal of Pediatric Gastroenterology and Nutrition, 66, 915-919 (2018).

K. Karmiris, I.E. Koutroubakis, C. Xidakis, M. Polychronaki, E.A. Kouroumalis, The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease, European Journal of Gastroenterology & Hepatology, 19, 789-794 (2007).

A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration, PLoS Medicine, 6, e1000100 (2009).

G.A. Wells, B. Shea, D. O’Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2009; URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, Accessed in February 26, 2020.

Z. Munn, S. Moola, D. Riitano, K. Lisy, The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence, International Journal of Health Policy and Management, 3, 123-128 (2014)

A. Gambero, M. Maróstica, M.J.A. Saad, J. Pedrazzoli, Mesenteric adipose tissue alterations resulting from experimental reactivated colitis, Inflammatory Bowel Disease, 13, 1357-1364 (2007)

S. Danese, Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker, Digestive and Liver Disease, 40, S225-S228 (2008).

C. Büning, C. von Kraft, M. Hermsdorf, E. Gentz, E.K. Wirth, L. Valentini, V. Haas, Visceral adipose tissue in patients with Crohnʼs disease correlates with disease activity, inflammatory markers, and outcome, Inflammatory Bowel Disease, 21, 2590-2597 (2015).

J.M. Bruun, S.B. Pedersen, K. Kristensen, B. Richelsen, Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro, Molecular and Cellular Endocrinology, 190, 91-99 (2002).

R.L. Fawcett, A.S. Waechter, L.B. Williams, P. Zhang, R. Louie, R. Jones, M. Inman, J. Huse, R.V. Considine, Tumor necrosis factor-α inhibits leptin production in subcutaneous and omental adipocytes from morbidly obese humans, Journal of Clinical Endocrinology and Metabolism, 85, 530-535 (2000).

M. Bokarewa, I. Nagaev, L. Dahlberg, U. Smith, A. Tarkowski, Resistin, an adipokine with potent proinflammatory properties, Journal Immunology, 174, 5789-5795 (2005).

G.H. Marques-Oliveira, T.M. Silva, W.G. Lima, H.M.S. Valadares, V.E. Chaves, Insulin as a hormone regulator of the synthesis and release of leptin by white adipose tissue, Peptides, 106, 49-58 (2018).

S.R. Bornstein, J. Licinio, R. Tauchnitz, L. Engelmann, A. Negrão, P. Gold, G.P. Chrousos, Plasma leptin levels are increased in survivors of acute sepsis: Associated loss of diurnal rhythm in cortisol and leptin secretion, Journal of Clinical Endocrinology and Metabolism, 83, 280-283 (1998).

K. Karmiris, I.E. Koutroubakis, E.A. Kouroumalis, Leptin, adiponectin, resistin, and ghrelin - Implications for inflammatory bowel disease, Molecular Nutrition & Food Research, 52, 855-866 (2008).

M. Rosenbaum, M. Nicolson, J. Hirsch, E. Murphy, F. Chu, R.L. Leibel, Effects of weight change on plasma leptin concentrations and energy expenditure, Journal of Clinical Endocrinology and Metabolism, 82, 3647-3654 (1997).

M. Rosenbaum, R.L. Leibel, J. Hirsch, Obesity, New England Journal of Medicine, 337, 396-407 (1997).

M.S. Jamaluddin, S.M. Weakley, Q. Yao, C. Chen, Resistin: Functional roles and therapeutic considerations for cardiovascular disease, Brazilian Journal of Pharmacology, 165, 622-632 (2012).

H.K. Park, R.S. Ahima, Resistin in Rodents and Humans, Diabetes and Metabolism Journal, 37, 404-414 (2013).

H.K. Park, M.K. Kwak, H.J. Kim, R.S. Ahima, Linking resistin, inflammation, and cardiometabolic diseases, Korean Journal of Internal Medicine, 32, 239-247 (2017).

L. Patel, A.C. Buckels, I.J. Kinghorn, P.R. Murdock, J.D. Holbrook, C. Plumpton, C.H. Macphee, S.A. Smith, Resistin is expressed in human macrophages and directly regulated by PPARγ activators, Biochemical and Biophysical Research Communications, 300, 472-476 (2003).

T.R.L. Clemente, A.N. Dos Santos, J.N. Sturaro, É.M.F. Gotardo, C.C. De Oliveira, S.C. Acedo, C.R.E.P. Caria, J. Pedrazzoli, M.L. Ribeiro, A. Gambero, Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis, Scandinavian Journal of Gastroenterology, 47, 943-950 (2012).

S. Kaser, A. Kaser, A. Sandhofer, C.. Ebenbichler, H. Tilg, J.. Patsch, Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro, Biochemical and Biophysical Research Communications, 309, 286–290 (2003).

A.E. Achari, S.K. Jain, Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction, International Journal of Molecular Sciences, 18, 1321 (2017).

G. Fantuzzi, Adiponectin in inflammatory and immune-mediated diseases, Cytokine, 64, 1-10 (2013).

C. Weidinger, J.F. Ziegler, M. Letizia, F. Schmidt, B. Siegmund, Adipokines and their role in intestinal inflammation, Frontiers in Immunology, 9, 1974 (2018).

K. Yamamoto, T. Kiyohara, Y. Murayama, S. Kihara, Y. Okamoto, T. Funahashi, T. Ito, R. Nezu, S. Tsutsui, J.-I. Miyagawa, S. Tamura, Y. Matsuzawa, I. Shimomura, Y. Shinomura, Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn’s disease, Gut, 54, 789-796 (2005).

H.S.H. Al-Khalidy, R.M. Hasan, B.M. Mahdi, Role of adiponectin in patients with inflammatory bowel disease unclassified, Journal of Coloproctology, 38, 320- 323 (2018).

Cómo citar

APA

Lima, W. G., Alcântara Cândido, P., de Paula Sabino, A., Nascimento Cardoso, V. y Antunes Fernandes, S. O. (2023). Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis. Revista Colombiana de Ciencias Químico-Farmacéuticas, 51(3). https://doi.org/10.15446/rcciquifa.v51n3.107328

ACM

[1]
Lima, W.G., Alcântara Cândido, P., de Paula Sabino, A., Nascimento Cardoso, V. y Antunes Fernandes, S.O. 2023. Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis. Revista Colombiana de Ciencias Químico-Farmacéuticas. 51, 3 (mar. 2023). DOI:https://doi.org/10.15446/rcciquifa.v51n3.107328.

ACS

(1)
Lima, W. G.; Alcântara Cândido, P.; de Paula Sabino, A.; Nascimento Cardoso, V.; Antunes Fernandes, S. O. Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis. Rev. Colomb. Cienc. Quím. Farm. 2023, 51.

ABNT

LIMA, W. G.; ALCÂNTARA CÂNDIDO, P.; DE PAULA SABINO, A.; NASCIMENTO CARDOSO, V.; ANTUNES FERNANDES, S. O. Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis. Revista Colombiana de Ciencias Químico-Farmacéuticas, [S. l.], v. 51, n. 3, 2023. DOI: 10.15446/rcciquifa.v51n3.107328. Disponível em: https://revistas.unal.edu.co/index.php/rccquifa/article/view/107328. Acesso em: 20 abr. 2025.

Chicago

Lima, William Gustavo, Patrícia Alcântara Cândido, Adriano de Paula Sabino, Valbert Nascimento Cardoso, y Simone Odília Antunes Fernandes. 2023. «Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis». Revista Colombiana De Ciencias Químico-Farmacéuticas 51 (3). https://doi.org/10.15446/rcciquifa.v51n3.107328.

Harvard

Lima, W. G., Alcântara Cândido, P., de Paula Sabino, A., Nascimento Cardoso, V. y Antunes Fernandes, S. O. (2023) «Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis», Revista Colombiana de Ciencias Químico-Farmacéuticas, 51(3). doi: 10.15446/rcciquifa.v51n3.107328.

IEEE

[1]
W. G. Lima, P. Alcântara Cândido, A. de Paula Sabino, V. Nascimento Cardoso, y S. O. Antunes Fernandes, «Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis», Rev. Colomb. Cienc. Quím. Farm., vol. 51, n.º 3, mar. 2023.

MLA

Lima, W. G., P. Alcântara Cândido, A. de Paula Sabino, V. Nascimento Cardoso, y S. O. Antunes Fernandes. «Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis». Revista Colombiana de Ciencias Químico-Farmacéuticas, vol. 51, n.º 3, marzo de 2023, doi:10.15446/rcciquifa.v51n3.107328.

Turabian

Lima, William Gustavo, Patrícia Alcântara Cândido, Adriano de Paula Sabino, Valbert Nascimento Cardoso, y Simone Odília Antunes Fernandes. «Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis». Revista Colombiana de Ciencias Químico-Farmacéuticas 51, no. 3 (marzo 23, 2023). Accedido abril 20, 2025. https://revistas.unal.edu.co/index.php/rccquifa/article/view/107328.

Vancouver

1.
Lima WG, Alcântara Cândido P, de Paula Sabino A, Nascimento Cardoso V, Antunes Fernandes SO. Serum adipokines as biomarkers for the therapeutic monitoring of patients with inflammatory bowel diseases (IBDs) treated with infliximab: a systematic review and meta-analysis. Rev. Colomb. Cienc. Quím. Farm. [Internet]. 23 de marzo de 2023 [citado 20 de abril de 2025];51(3). Disponible en: https://revistas.unal.edu.co/index.php/rccquifa/article/view/107328

Descargar cita

CrossRef Cited-by

CrossRef citations0

Dimensions

PlumX

Visitas a la página del resumen del artículo

256

Descargas

Los datos de descargas todavía no están disponibles.

Licencia

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.

El Departamento de Farmacia de la Facultad de Ciencias de la Universidad Nacional de Colombia  autoriza la fotocopia de artículos y textos para fines de uso académico o interno de las instituciones citando la fuente. Las ideas emitidas por los autores son responsabilidad expresa de estos y no de la revista.

Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons de Atribución 4.0 aprobada en Colombia. Consulte la normativa en: http://co.creativecommons.org/?page_id=13